Structural studies of the phosphatidylinositol 3-kinase (PI3K) SH3 domain in complex with a peptide ligand: Role of the anchor residue in ligand binding

Biological Chemistry

Volumn 391, Issue 1, 2010, Pages 33-42

  Batra Safferling, Renu ^a   Granzin, Joachim ^a   Mödder, Susanne ^a   Hoffmann, Silke ^a   Willbold, Dieter ^a,b  

^a FORSCHUNGSZENTRUM JÜLICH   (Germany)

^b HEINRICH HEINE UNIVERSITY   (Germany)

Author keywords

stacking; Phosphatidylinositol 3 kinase; Polyproline helix; Protein ligand interaction; Src homology 3

Indexed keywords

ARGININE; PEPTIDE; PHOSPHATIDYLINOSITOL 3 KINASE; PROTEIN SH3; TRYPTOPHAN; TYROSINE;

AMINO ACID SEQUENCE; ARTICLE; BINDING KINETICS; BINDING SITE; CHEMICAL STRUCTURE; CONTROLLED STUDY; CRYSTALLIZATION; LIGAND BINDING; MOLECULE; PRIORITY JOURNAL; PROTEIN CONFORMATION; PROTEIN PROTEIN INTERACTION;

1-PHOSPHATIDYLINOSITOL 3-KINASE; AMINO ACID SEQUENCE; BINDING SITES; CRYSTALLOGRAPHY, X-RAY; LIGANDS; MODELS, MOLECULAR; MOLECULAR SEQUENCE DATA; OLIGOPEPTIDES; PEPTIDES; PROTEIN BINDING; SRC HOMOLOGY DOMAINS;

EID: 75149184920     PISSN: 14316730     EISSN: 14374315     Source Type: Journal    
DOI: 10.1515/BC.2010.003     Document Type: Article

References (42)

1. Adams, P.D., Grosse-Kunstleve, R.W., Hung, L.-W., Ioerger, T.R., McCoy, A.J., Moriarty, N.W., Read, R.J., Sacchettini, J.C., Sauter, N.K., and Terwilliger, T.C. (2002). PHENIX: building new software for automated crystallographic structure determination. Acta Cryst. D58, 1948-1954.
2. Booker, G.W., Gout, I., Downing, A.K., Driscoll, P.C., Boyd, J., Waterfield, M.D., and Campbell, I.D. (1993). Solution structure and ligand-binding site of the SH3 domain of the p85 a subunit of phosphatidylinositol 3-kinase. Cell 73, 813-822.
3. DeLano, W.L. (2008). The PyMOL Molecular Graphics System (Palo Alto, CA, USA: DeLano Scientific LLC), http://www. pymol.org.
4. de Vos, A.M., Ultsch, M., and Kossiakoff, A.A. (1992). Human growth hormone and extracellular domain of its receptor: crystal structure of the complex. Science 255, 306-312.
5. Faux, M.C. and Scott, J.D. (1996). More on target with protein phosphorylation: conferring specificity by location. Trends Biochem. Sci. 21, 312-315.
6. Feng, S., Chen, J.K., Yu, H., Simon, J.A., and Schreiber, S.L. (1994). Two binding orientations for peptides to the Src SH3 domain: development of a general model for SH3-ligand interactions. Science 266, 1241-1247.
7. Fernandez-Ballester, G., Blanes-Mira, C., and Serrano, L. (2004). The tryptophan switch: changing ligand-binding specificity from type I to type II in SH3 domains. J. Mol. Biol. 335, 619-629.
8. Franz, W.M., Berger, P., and Wang, J.Y. (1989). Deletion of an Nterminal regulatory domain of the c-abl tyrosine kinase activates its oncogenic potential. EMBO J. 8, 137-147.
9. Fruman, D.A., Meyers, R.E., and Cantley, L.C. (1998). Phosphoinositide kinases. Annu. Rev. Biochem. 67, 481-507.
10. Hanks, S.K. and Hunter, T. (1995). Protein kinases 6. The eukaryotic protein kinase superfamily: kinase (catalytic) domain structure and classification. FASEB J. 9, 576-596.
11. Hiles, I.D., Otsu, M., Volinia, S., Fry, M.J., Gout, I., Dhand, R., Panayotou, G., Ruiz-Larrea, F., Thompson, A., Totty, N.F., et al. (1992). Phosphatidylinositol 3-kinase: structure and expression of the 110 kd catalytic subunit. Cell 70, 419-429.
12. Jackson, P. and Baltimore, D. (1989). N-terminal mutations activate the leukemogenic potential of the myristoylated form of c-abl. EMBO J. 8, 449-456.
13. Jones, T.A., Zou, J.-Y., Cowan, S.W., and Kjeldgaard, M. (1991). Improved methods for the building of protein models in electron density maps and the location of errors in these models. Acta Crystallogr. A47, 110-119.
14. Kabsch, W. and Sander, C. (1983). Dictionary of protein secondary structure: pattern recognition of hydrogen-bonded and geometrical features. Biopolymers 22, 2577-2637.
15. Kaplan, K.B., Bibbins, K.B., Swedlow, J.R., Arnaud, M., Morgan D.O., and Varmus, H.E. (1994). Association of the amino-terminal half of c-Src with focal adhesions alters their properties and is regulated by phosphorylation of tyrosine 527. EMBO J. 13, 4745-4756.
16. Katso, R., Okkenhaug, K., Ahmadi, K., White, S., Timms, J., and Waterfield, M.D. (2001). Cellular function of phosphoinositide 3-kinases: implications for development, homeostasis, and cancer. Annu. Rev. Cell Dev. Biol. 17, 615-675.
17. Knight, Z.A., Gonzalez, B., Feldman, M.E., Zunder, E.R., Goldenberg, D.D., Williams, O., Loewith, R., Stokoe, D., Balla, A., Toth, B., et al. (2006). A pharmacological map of the PI3-K family defines a role for p110a in insulin signaling. Cell 125, 733-747.
18. Koch, C.A., Anderson, D., Moran, M.F., Ellis, C., and Pawson, T. (1991). SH2 and SH3 domains: elements that control interactions of cytoplasmic signaling proteins. Science 252, 668-674.
19. Koyama, S., Yu, H., Dalgarno, D.C., Shin, T.B., Zydowsky, L.D., and Schreiber, S.L. (1993). Structure of the PI3K SH3 domain and analysis of the SH3 family. Cell 72, 945-952.
20. Kraulis, P.J. (1991). MOLSCRIPT: a program to produce both detailed and schematic plots of protein structures. J. Appl. Cryst. 24, 946-950.
21. Kuriyan, J. and Cowburn, D. (1997). Modular peptide recognition domains in eukaryotic signaling. Annu. Rev. Biophys. Biomol. Struct. 26, 259-288.
22. Larson, S.M. and Davidson, A.R. (2000). The identification of conserved interactions within the SH3 domain by alignment of sequences and structures. Protein Sci. 9, 2170-2180.
23. Leslie, A.G.W. (1992). Recent changes to the MOSFLM package for processing film and image plate data. Jnt. CCP4/ESFEAMCB Newslett. Protein Crystallogr. 26.
24. Liang, J., Chen, J.K., Schreiber, S.T., and Clardy, J. (1996). Crystal structure of P13K SH3 domain at 2 Å resolution. J. Mol. Biol. 257, 632-643.
25. Lim, W.A., Richards, F.M., and Fox, R.O. (1994). Structural determinants of peptide-binding orientation and of sequence specificity in SH3 domains. Nature 372, 375-379.
26. Livnah, O., Stura, E.A., Johnson, D.L., Middleton, S.A., Mulcahy, L.S., Wrighton, N.C., Dower, W.J., Jolliffe, L.K., and Wilson, I.A. (1996). Functional mimicry of a protein hormone by a peptide agonist: the EPO receptor complex at 2.8 Å . Science 273, 464-471.
27. Meng, E.C., Pettersen, E.F., Couch, G.S., Huang, C.C., and Ferrin, T.E. (2006). Tools for integrated sequence-structure analysis with UCSF Chimera. BMC Bioinformatics 7, 339.
28. Merritt, E.A. and Bacon, D.J. (1997). Raster3D photorealistic molecular graphics. Methods Enzymol. 277, 505-524.
29. Musacchio, A. (2002). How SH3 domains recognize proline. Adv. Protein Chem. 61, 211-268.
30. Musacchio, A., Gibson, T., Lehto, V.P., and Saraste, M. (1992). SH3: an abundant protein domain in search of a function. FEBS Lett. 307, 55-61.
31. Otsu, M., Hiles, I., Gout, I., Fry, M.J., Ruiz-Larrea, F., Panayotou, G., Thompson, A., Dhand, R., Hsuan, J., Totty, N., et al. (1991). Characterization of two 85 kD proteins that associate with receptor tyrosine kinases, middle-T/pp60c-src complexes, and PI3- kinase. Cell 65, 91-104.
32. Pawson, T. and Gish, G.D. (1992). SH2 and SH3 domains: from structure to function. Cell 71, 359-362.
33. Pawson, T. and Schlessinger, J. (1993). SH2 and SH3 domains. Curr. Biol. 3, 434-442.
34. Rodrigues, G.A., Park, M., and Schlessinger, J. (1997). Activation of the JNK pathway is essential for transformation by the Met oncogene. EMBO J. 16, 2634-2645.
35. Schmidt, H., Hoffmann, S., Tran, T., Stoldt, M., Stangler, T., Wiesehan, K., and Willbold, D. (2007). Solution structure of a Hck SH3 domain ligand complex reveals novel interaction modes. J. Mol. Biol. 365, 1517-1532.
36. Skolnik, E.Y., Margolis, B., Mohammadi, M., Lowenstein, E., Fischer, R., Drepps, A., Ullrich, A., and Schlessinger, J. (1991). Cloning of PI3 kinase-associated p85 utilizing a novel method for expression/cloning of target proteins for receptor tyrosine kinases. Cell 65, 83-90.
37. Stangler, T., Tran, T., Hoffmann, S., Schmidt, H., Jonas, E., and Willbold, D. (2007). Competitive displacement of full-length HIV-1 Nef from the Hck SH3 domain by a high-affinity artificial peptide. Biol. Chem. 388, 611-615.
38. Stout, T.J., Foster, P.G., and Matthews, D.J. (2004). High-throughput structural biology in drug discovery: protein kinases. Curr. Pharm. Des. 10, 1069-1082.
39. Superti-Furga, G., Fumagalli, S., Koegl, M., Courtneidge, S.A., and Draetta, G. (1993). Csk inhibition of c-Src activity requires both the SH2 and SH3 domains of Src. EMBO J. 12, 2625-2634.
40. Tran, T., Hoffmann, S., Wiesehan, K., Jonas, E., Luge, C., Aladag, A., and Willbold, D. (2005). Insights into human Lck SH3 domain binding specificity: different binding modes of artificial and native ligands. Biochemistry 44, 15042-15052.
41. Weng, Z., Thomas, S.M., Rickles, R.J., Taylor, J.A., Brauer, A.W., Seidel-Dugan, C., Michael, W.M., Dreyfuss, G., and Brugge, J.S. (1994). Identification of Src, Fyn, and Lyn SH3-binding proteins: implications for a function of SH3 domains. Mol. Cell. Biol. 14, 4509-4521.
42. Yu, H., Chen, J.K., Feng, S., Dalgarno, D.C., Brauer A.W., and Schreiber, S.L. (1994). Structural basis for the binding of proline- rich peptides to SH3 domains. Cell 76, 933-945.